# CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI

Study · id `cardio:ct-nct03296540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03296540](<https://clinicaltrials.gov/study/NCT03296540>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03296540

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 729 participants.

## Technical summary

Registry record NCT03296540. Randomized; no masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2021-05-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 729 participants (enrolled count; ClinicalTrials.gov record NCT03296540, source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)
- Started: 2017-11-28 (actual) (ClinicalTrials.gov record NCT03296540, source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)
- Primary completion: 2021-05-01 (actual) (ClinicalTrials.gov record NCT03296540, source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)
- Completion: 2021-05-01 (actual) (ClinicalTrials.gov record NCT03296540, source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT03296540, source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03296540-2021-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
- Acronym: CompareCrush
- Condition: Cardiovascular Diseases
- Intervention (Drug): Prasugrel (Crushed tablets)
- Intervention (Drug): Prasugrel (Integral tablets)
- Lead sponsor: Maasstad Hospital
- Lead sponsor class: OTHER
- Collaborator: MicroPort Orthopedics Inc.
- Collaborator class: INDUSTRY
- Collaborator: Daiichi Sankyo
- Collaborator class: INDUSTRY
- Collaborator: Research Maatschap Cardiologen Rotterdam Zuid
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Prasugrel (`cardio:prasugrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Maasstad Hospital (`cardio:org-maasstad-hospital`)
- Registry lists this organization as a collaborator: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: b625a48e62862f871ce92b348c8637e95878cf4cc7deddc31ada2df65d2c4a88
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
